DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to find out how well an experimental drug called DepoCyt works for neoplastic meningitis (cancer that has spread to the tissues around the brain and spinal cord). DepoCyt is a new slow-release form of the cancer drug called ara-C (cytarabine). Cytarabine has been used for many years to treat cancer.
Condition or disease
Drug: Intrathecal (injected into the spinal fluid) DepoCytDrug: Intrathecal methotrexateDrug: Intrathecal cytarabine (also known as ara-C)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosed (or previously diagnosed) with lymphoma or a solid tumor (not leukemia)
Diagnosed with neoplastic meningitis
If female, not pregnant and will not become pregnant while on-study
No other experimental therapy within 21 days of participation
Central Nervous System Diseases
Nervous System Diseases
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Abortifacient Agents, Nonsteroidal
Reproductive Control Agents